This content is from: International As good as new: why IP is central to repurposed drugs Sources from the pharmaceutical industry explain why research organisations should learn about IP before trying to bring an approved drug to market By Charlotte Kilpatrick April 15 2021
This content is from: United States Road to success: in-house on the Patent Prosecution Highway By Rani Mehta April 15 2021
This content is from: United Kingdom Incopro: Enabling rights owners to ‘redress the imbalance’ By Prin Shasiharan April 15 2021
This content is from: South Korea Drug pricing policy in South Korea revised to ‘tiered pricing system’ By Min Son April 14 2021
This content is from: Patents Podcast masterclass: A primer on filing IP in Africa By Charlotte Kilpatrick April 14 2021
This content is from: China Editorial - MIP's China Special Focus launched By Lorraine Yardley April 14 2021
This content is from: China How the Anti-Unfair Competition Law will protect IP rights in China By Bin Zhang & Lei Fu April 14 2021
This content is from: China The strategy of collecting evidence in Chinese IP infringement cases Xiaodong Ren and Xiaojun Liu of Beijing Kangrui Law Firm explain the techniques that legal teams can take during the evidence collection stages of IP disputes By Xiaodong Ren & Xiaojun Liu April 14 2021
